Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ for Fatigue in Multiple Sclerosis
NCT03166800Phase 2Terminated
- Sponsor
- Oregon Health & Science University
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitoquinone in fatigue, sponsored by Oregon Health & Science University. Primary endpoint: Modified Fatigue Impact Scale at 12 weeks. Started Sep 2018; status: terminated.
02
Drugs
mitoquinone
03
Conditions
fatigue
Beyond the preview
Go deeper on NCT03166800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166800.